We concluded that acquired resistance of breast cancer cells to anti-HER2 therapies, even when concomitant with the loss of HER2 protein expression, is not due to the elimination of DMs encoding the tyrosine kinase receptor. This evidence concerns the gene ERBB2 and breast cancer.